RE: Share Price24 Nov 2025 16:09
As would be expected, discussions cover a broad spectrum of subjects including scientific, technical and commercial aspects of P140 and by their nature these are, and continue to be, detailed and time consuming.
ImmuPharma's objective is to identify "the best fit" partner for P140's further development and commercialisation and to secure the best possible deal for ImmuPharma's shareholders.
To this end, based on the engagements with potential partners to date, the Board now expects the completion of any partnership deal to extend beyond the end of 2025, with our aim being to move to completion of a deal as soon as practicable in 2026.
You guys must speak a different language to me.